Gregg Gilbert
Stock Analyst
(2.91)
# 4,648
Out of 4,648 analysts
91
Total ratings
55.56%
Success rate
5.56%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.11 | +68.15% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $32.72 | +13.08% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $55.45 | +51.49% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $430 → $525 | $806.14 | -34.87% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $16.42 | -20.83% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $16.59 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $101.87 | -8.71% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $8.72 | +450.46% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $0.67 | +3,780.60% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.57 | +26,336.38% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $25.41 | +206.97% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $175.18 | -55.47% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $18.64 | -3.43% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $110.22 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $109.41 | +59.95% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $200.47 | -67.08% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.11
Upside: +68.15%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $32.72
Upside: +13.08%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $55.45
Upside: +51.49%
Eli Lilly
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $806.14
Upside: -34.87%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $16.42
Upside: -20.83%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $16.59
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $101.87
Upside: -8.71%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $8.72
Upside: +450.46%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.67
Upside: +3,780.60%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.57
Upside: +26,336.38%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $25.41
Upside: +206.97%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $175.18
Upside: -55.47%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $18.64
Upside: -3.43%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $110.22
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $109.41
Upside: +59.95%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $200.47
Upside: -67.08%